Ozempic Medicare Part D Coverage: What You Actually Pay in 2026

Does Medicare Part D Cover Ozempic?

Yes, but the coverage applies exclusively to the FDA-approved indication of type 2 diabetes management. The Centers for Medicare & Medicaid Services (CMS) requires that Ozempic be prescribed for glycemic control, not for weight management alone. Wegovy (semaglutide 2.4 mg) holds the obesity indication, yet Medicare has historically excluded anti-obesity medications under the Social Security Act, Section 1862(a)(1)(A).

Part D plans include Ozempic on their formularies as a brand-name injectable, typically placed on Tier 3 or Tier 4. Tier placement directly determines your copay or coinsurance percentage. A Tier 3 placement might carry a $47 copay per fill, while Tier 4 could mean 25-33% coinsurance on a drug that lists near $998 per month 1. Each plan's formulary is different, so checking your specific plan's drug list on Medicare.gov before enrollment season is a practical first step.

Most Part D plans also impose prior authorization. Your prescriber will need to document that you have a diagnosis of type 2 diabetes, that you have tried or cannot tolerate metformin, and that your HbA1c remains above target. Step therapy requirements vary. Some plans require failure on a sulfonylurea or DPP-4 inhibitor before approving a GLP-1 receptor agonist 2.

The $2,000 Out-of-Pocket Cap Changes the Math

The Inflation Reduction Act restructured Medicare Part D cost sharing, and the single biggest change for Ozempic users is the $2,000 annual out-of-pocket maximum that began on January 1, 2025. Before this cap, beneficiaries in the coverage gap (the so-called "donut hole") could face thousands of dollars in annual spending on high-cost brand injectables like semaglutide 3.

Here is what this means in practice. If Ozempic is your most expensive medication and your plan places it on Tier 4 with 25% coinsurance, you would hit the $2,000 cap within roughly two to three months of fills. After reaching that threshold, you pay $0 for the remainder of the calendar year. That is a dramatic shift from the pre-IRA structure, where catastrophic-phase cost sharing continued at 5% indefinitely.

The Medicare Prescription Payment Plan adds another layer of relief. This optional program, also introduced under the IRA, lets you spread your annual out-of-pocket costs into predictable monthly installments rather than paying large lump sums at the pharmacy counter. Enrollment is available through your Part D plan or Medicare Advantage plan with drug coverage 4.

"The $2,000 cap is the most consequential change to Part D benefit design since the program launched in 2006," noted CMS Administrator Chiquita Brooks-LaSure in a 2024 CMS press briefing. "Beneficiaries taking expensive brand-name drugs like GLP-1 receptor agonists will see their exposure cut by thousands of dollars annually."

How Prior Authorization Works for Ozempic Under Part D

Getting the prior authorization approved is the step where most delays happen. Your physician's office submits clinical documentation to the plan, and the plan's pharmacy benefit manager reviews it against coverage criteria.

Typical requirements include a confirmed type 2 diabetes diagnosis (ICD-10 code E11.x), a recent HbA1c value (usually 7.0% or above), documentation that metformin was tried for at least 90 days or is contraindicated due to renal impairment (eGFR <30 mL/min) or gastrointestinal intolerance, and sometimes evidence that another second-line agent was attempted. The American Diabetes Association's Standards of Care recommend GLP-1 receptor agonists as preferred second-line therapy for patients with established atherosclerotic cardiovascular disease or high cardiovascular risk, which can strengthen the clinical justification 5.

Turnaround time is typically 24-72 hours for a standard request. Urgent or expedited requests, appropriate when a patient is experiencing hyperglycemic symptoms, must be processed within 24 hours under CMS rules. If your authorization is denied, you have the right to a Coverage Determination appeal, followed by an Independent Review Entity (IRE) appeal if the plan upholds its denial 6.

Ozempic Cost Breakdown: What Each Coverage Phase Looks Like

Understanding Part D's benefit phases helps you predict monthly spending. The 2026 structure, based on CMS final rule parameters, breaks down into four phases.

Deductible phase. The standard Part D deductible for 2026 is projected near $590 (CMS adjusts annually). You pay 100% of the drug cost until you meet this amount. One Ozempic fill at the negotiated plan price could satisfy the entire deductible in a single month.

Initial coverage phase. After the deductible, you pay your plan's copay or coinsurance. For a Tier 4 drug, expect 25-33% of the negotiated price. If your plan's negotiated rate for Ozempic is $850 per month, you would pay $212-$280 per fill during this phase.

Coverage gap (donut hole). Under the IRA's redesigned benefit, manufacturers now bear a larger share of costs in this phase. Your out-of-pocket cost during the gap dropped substantially, and all spending in this phase counts toward the $2,000 cap.

Catastrophic phase. Once your true out-of-pocket spending hits $2,000, you pay nothing for the rest of the year. No coinsurance, no copays. This is where the IRA made the largest difference for patients on expensive injectables 7.

For most Ozempic users on Part D, the $2,000 cap will be reached within the first three to four months of the year, resulting in eight to nine months of zero-cost refills.

The Novo Nordisk Savings Card and Its Medicare Limitation

Novo Nordisk offers the Ozempic Savings Card for commercially insured patients, which can reduce copays to as little as $25 per fill for up to 24 months. There is one catch that trips up many beneficiaries. Federal law prohibits the use of manufacturer copay cards for patients enrolled in Medicare, Medicaid, or other federally funded programs. This is not a Novo Nordisk policy. It is an anti-kickback statute requirement enforced by the Office of Inspector General 8.

This means if you have Medicare Part D, you cannot use the Savings Card at all. The program is exclusively for patients with private commercial insurance. Attempting to use it could create legal and billing complications for both you and your pharmacy.

However, Novo Nordisk does operate a separate Patient Assistance Program (PAP) for patients who are uninsured or who fall into specific financial hardship categories. Eligibility is income-based, generally requiring household income at or below 400% of the federal poverty level. Approved applicants may receive Ozempic at no cost for a defined period, with annual re-certification required 9.

Strategies to Lower Ozempic Costs on Medicare

Even with the $2,000 cap, the first few months of the year involve real spending. Several approaches can reduce that burden further.

Choose your Part D plan carefully during open enrollment. Plans vary widely in how they tier Ozempic. A plan that places semaglutide on Tier 3 (preferred brand) instead of Tier 4 (non-preferred brand) could save you $50-$100 per fill during the initial coverage phase. The Medicare Plan Finder at Medicare.gov lets you enter your specific medications and compare total estimated annual costs across all available plans in your zip code.

Enroll in the Medicare Prescription Payment Plan. Spreading your $2,000 maximum across 12 monthly payments of approximately $167 is more manageable than paying $590 in month one, $280 in month two, and so on. This is an interest-free installment program, not a loan.

Ask about therapeutic alternatives. If prior authorization is denied or cost remains prohibitive, your physician may consider dulaglutide (Trulicity) or tirzepatide (Mounjaro), which may sit on a more favorable formulary tier depending on your plan. The SUSTAIN-7 trial (N=1,201) demonstrated that semaglutide 1 mg achieved a 1.8% HbA1c reduction vs. 1.4% for dulaglutide 1.5 mg at 40 weeks, but the cost difference between these agents under a specific plan may outweigh the incremental efficacy 10.

Explore Extra Help (Low-Income Subsidy). Medicare's Extra Help program covers most or all Part D costs for beneficiaries with limited income and resources. In 2025, the income threshold expanded under the IRA so that those earning up to 150% of the federal poverty level qualify for full benefits, which can reduce Ozempic copays to $0-$4.50 per fill 11.

Consider a Medicare Advantage plan with integrated drug coverage. Some MA-PD plans negotiate aggressive GLP-1 pricing. Compare total out-of-pocket projections, not just monthly premiums.

Why Medicare Does Not Cover Ozempic for Weight Loss

This is a common source of confusion. Ozempic (semaglutide 0.5-2.0 mg) is FDA-approved only for type 2 diabetes. Wegovy (semaglutide 2.4 mg) holds the approval for chronic weight management. But even if your doctor prescribed Wegovy, Medicare Part D historically excluded anti-obesity medications under statutory language in the Social Security Act 12.

Legislative efforts to change this exclusion have been introduced in Congress, most notably the Treat and Reduce Obesity Act (TROA). As of May 2026, this legislation has not been signed into law, though bipartisan support has grown. The Congressional Budget Office estimated that covering anti-obesity medications under Part D would cost approximately $35 billion over ten years, a figure that reflects both the drug prices and the projected uptake among the 42% of Medicare beneficiaries who meet obesity criteria 13.

If you have type 2 diabetes and obesity, your physician can prescribe Ozempic for the diabetes indication. The weight loss that occurs is a documented clinical benefit (the SUSTAIN trials consistently showed 4.5-6.5 kg weight reduction with semaglutide 1 mg over 30-56 weeks), but the primary coverage justification remains glycemic control 14.

"We recommend GLP-1 receptor agonists with proven cardiovascular benefit as preferred agents for patients with type 2 diabetes and established ASCVD, heart failure, or chronic kidney disease," states the 2024 ADA Standards of Care, Chapter 9.

Compounded Semaglutide: A Cheaper Option with Caveats

Compounded semaglutide, available from 503A and 503B compounding pharmacies at roughly $199 per month, has attracted patients who cannot afford brand-name Ozempic. The FDA has issued multiple warnings about compounded GLP-1 receptor agonists, citing concerns about sterility, dosing accuracy, and the use of semaglutide salt forms (such as semaglutide sodium) that differ from the FDA-approved formulation 15.

Medicare Part D does not cover compounded medications through standard formulary channels. You would pay entirely out of pocket. For a Medicare beneficiary who reaches the $2,000 cap early in the year, the math often favors staying with brand Ozempic through Part D rather than paying $199 per month year-round for a compounded product ($2,388 annually vs. $2,000 maximum).

The Endocrine Society released a position statement in 2024 advising clinicians to prescribe only FDA-approved GLP-1 receptor agonist formulations "unless the branded product is genuinely inaccessible, and even then to use only FDA-registered outsourcing facilities" 16.

Timeline: Getting Ozempic Covered Step by Step

A practical sequence for Medicare beneficiaries seeking Ozempic coverage:

1. Confirm your type 2 diabetes diagnosis with recent labs (HbA1c, fasting glucose).
2. Verify that metformin has been tried or is documented as contraindicated.
3. Use Medicare Plan Finder to identify which plans in your area cover Ozempic on a favorable tier.
4. During Part D open enrollment (October 15 through December 7), select the plan with the lowest projected total cost including premiums, deductible, and Ozempic coinsurance.
5. After enrollment, have your physician submit the prior authorization with supporting clinical documentation.
6. Enroll in the Medicare Prescription Payment Plan to spread the $2,000 cap across monthly installments.
7. Apply for Extra Help if your income is at or below 150% of the federal poverty level.

Your first fill will typically be the most expensive. Each subsequent fill pushes you closer to the $2,000 cap, after which you pay nothing for the rest of the calendar year.